Claire S. Padgett
Chief Tech/Sci/R&D Officer bei REGULUS THERAPEUTICS INC.
Profil
Claire S.
Padgett is a professional with experience in clinical operations.
She is currently the Senior Vice President of Clinical Operations at Regulus Therapeutics, Inc. Prior to her current position, she held similar roles at various pharmaceutical companies, including Executive Director of Clinical Operations at Conforma Therapeutics Corp., Vice President of Clinical Operations at Mast Therapeutics, Inc., Vice President of Clinical Operations at Oncolytics Biotech, Inc., and Vice President of Clinical Operations at Cylene Pharmaceuticals, Inc. She also served as Senior Vice President of Clinical Operations at Mirati Therapeutics, Inc. from 2017 to 2018.
Padgett received her undergraduate degree from Rutgers State University of New Jersey, her graduate degree and MBA from Seton Hall University, and her doctorate from Capella University LLC.
Aktive Positionen von Claire S. Padgett
| Unternehmen | Position | Beginn |
|---|---|---|
| REGULUS THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 29.11.2022 |
Ehemalige bekannte Positionen von Claire S. Padgett
| Unternehmen | Position | Ende |
|---|---|---|
| MIRATI THERAPEUTICS | Corporate Officer/Principal | 01.10.2018 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01.10.2018 |
Cylene Pharmaceuticals, Inc.
 Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Chief Operating Officer | 28.09.2010 |
| ONCOLYTICS BIOTECH INC. | Chief Tech/Sci/R&D Officer | - |
Conforma Therapeutics Corp.
 Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von Claire S. Padgett
| Rutgers State University of New Jersey | Undergraduate Degree |
| Seton Hall University | Graduate Degree |
| Capella University LLC | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ONCOLYTICS BIOTECH INC. | Health Technology |
| REGULUS THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
Cylene Pharmaceuticals, Inc.
Cylene Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cylene Pharmaceuticals, Inc. discovers, develops and commercializes small molecule drugs. It develops molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. The firm drug discovery platform, STAND has delivered a diverse portfolio of drug candidates that target the multiple pathways critical for the support, maintenance of cancer cells and that address unmet medical needs with substantial markets. The company was founded in 1997 by Thomas James Farrell and Daniel Douglas Von Hoff and is headquartered in San Diego, CA. | Health Technology |
Conforma Therapeutics Corp.
Conforma Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA. | Health Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
